Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Nogueira et al. have just published a new “mini-review” in BJU International that addresses the potential roles of current and “future” biomarkers that may have relevance to prostate cancer detection.
Filed under: Diagnosis, Risk | Tagged: biomarkers, detection | Leave a Comment »
A paper in press in the Journal of Urology has suggested that, for patients with intermediate-risk prostate cancer who elect treatment with a combination of standard (low dose) brachytherapy and external beam radiation therapy (EBRT), the addition of hormone therapy adds little in terms of clinical benefit.
Filed under: Management, Treatment | Tagged: ADT, androgen deprivation therapy, brachytherapy, combination radiotherapy, EBRT, external beam radiation therapy | Leave a Comment »
In a media release issued earlier today, the National Comprehensive Cancer Network (NCCN) has announced updates to the NCCN Clinical Practice Guidelines for Oncology™ for Prostate Cancer, and has placed a new emphasis on the value of active surveillance in management of men with low and very low risk of clinically significant disease.
Filed under: Management, Treatment, Uncategorized | Tagged: active surveillance, guidelines, National Comprehensive Cancer Network, NCCN | 7 Comments »
A paper from an Australian pathology group has suggested that, “Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension.”
Filed under: Diagnosis, Management, Risk | Tagged: carcinoma, ductal, pathology, risk | Leave a Comment »
A new paper by Armstrong et al. has analyzed data from the original TAX327 clinical trial in an attempt to define specific patient “risk groups” based on the participants in that trial and how they responded to docetaxel-based chemotherapy.
Filed under: Management, Treatment | Tagged: chemotherapy, docetaxel, outcomes, reponse, risk groups | Leave a Comment »
A new report has suggested that, for men already diagnosed with prostate cancer, “consumption of eggs and poultry with skin may increase the risk” of cancer recurrence or progression.
Filed under: Living with Prostate Cancer, Management | Tagged: chicken, eggs, poultry, progression, risk | 2 Comments »
Isbarn et al. (a German group working in Hamburg) have reported the first long-term survival data in response to radical prostatectomy (RP) from a European country since the beginning of the PSA era.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: long-term, outcomes, PSA era, radical prostatectomy | 2 Comments »
Recent reports have addressed the following issues related to prostate cancer: How many biopsy cores is the right number? How “open” surgeons have adapted to laparoscopic surgery Hypoxia, the tumor environment, and how it affects treatment Gefitinib + radiation therapy in intermediate- and high-risk prostate cancer Fractures, prostate cancer, and androgen deprivation
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: ADT, androgen deprivation therapy, biopsy, fractures, gefitinib, hypoxia, Iressa, microenvironment, radical prostatectomy, tumor | Leave a Comment »
A review by Epstein in an upcoming issue of the Journal of Urology gives a detailed perspective on the current use of the Gleason grading system, with specific emphasis on the “removal” of Gleason patterns 1 and 2 in evaluating overall Gleason scores of biopsy samples and the value of “tertiary” Gleason pattern data.
Filed under: Diagnosis, Management, Uncategorized | Tagged: Gleason, grade, modified, pattern, score, system | 6 Comments »
New animal research has suggested that the telomerase inhibitor imetelstat may have activity in the treatment of prostate cancer.
Filed under: Drugs in development | Tagged: imetelstat, inhibitor, telomerase | 1 Comment »
A few days ago we suggested that the role of positron emission tomography (PET scanning) as a diagnostic and prognostic tool in patients with prostate cancer was probably best limited to research studies at major medical centers at the present time. A recent study from Germany appears to confirm this suggestion.
Filed under: Diagnosis, Management, Risk | Tagged: lymph nodes, PET scan, positron emission tomography | 3 Comments »
A new paper by Wang et al. in a recent issue of Cancer Research has proposed details of a specific connection between control over the growth and division of prostate cancer cells and clinical occurrence of the more aggressive forms of prostate cancer.
Filed under: Management, Risk | Tagged: aggressive, cell, indolent, messenger RNA, microRNA, regulation | 3 Comments »
We have learned that last October the “Federaal Kenniscentrum voor de Gezondheidszorg” or KCE in Brussels, Belgium (the “Federal Center for Health Care Knowledge”) published a guidance document on the current use of high-intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer.
Filed under: Management, Treatment | Tagged: Belgium, HIFU, high-intensity focused ultrasound | 4 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site